Bone News and Research

RSS

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

As a result of research performed by scientists at the University of Maryland School of Medicine, the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neulasta, is one of a very small number that have been approved for the treatment of acute radiation injury.

21 Jan 2016

$Novel technique helps identify diabetic patients at risk of bone fractures$

Novel technique helps identify diabetic patients at risk of bone fractures

A Southampton study using high resolution imaging to create a "virtual bone biopsy" has shed new light on why people with type 2 diabetes are at risk of bone fractures.

20 Jan 2016

IMP, WEHI scientists successfully characterize central regulator of plasma cell function

Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.

20 Jan 2016

New clinical imaging method may enable doctors to tackle lung infections

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

19 Jan 2016

UConn-led researchers identify specific gene linked to Hajdu-Cheney syndrome

Fragile bones are usually an old person's affliction, but sometimes children are born with them. Now, a team of researchers led by UConn professor Ernesto Canalis has shown in mice that a specific gene can cause the disease, called Hajdu-Cheney syndrome. Overabundant bone-absorbing cells may be causing the disorder's characteristic bone loss, and the researchers hope to find a potential treatment.

18 Jan 2016

New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

A new study from the Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, shows lesions, which can best be seen on MRI scans, could help identify individuals who are more likely to suffer from more rapidly progressing osteoarthritis.

18 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

IQWiG finds no added benefit for pomalidomide drug in multiple myeloma

Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.

13 Jan 2016

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

In humans the differentiation of stem cells into hundreds of specialized cell types is vital. Differentiation drives development from fertilized egg to a newborn, and it underlies the continuous replacement of the 5 billion cells that die every hour in an adult. On the downside, mutations in differentiation pathways of different cell types can be drivers of cancers.

13 Jan 2016

Mechanical properties of bone revealed through micro-indentation testing

Unravelling the mechanical properties of bone with micro-indentation testing has significance in both health and disease. At the University Medical Center Hamburg-Eppendorf, Dr. Björn Busse and his research group have advanced their micro-indentation testing technique using an Olympus industrial inspection digital light microscope, as an alternative to electron microscopy. The cutting edge research is described in a new application note from Olympus, available online.

From Evident Corporation - Life Sciences 12 Jan 2016

Increasing levels of FGF21 hormone protects against loss of immune function in the elderly

A hormone that extends lifespan in mice by 40% is produced by specialized cells in the thymus gland, according to a new study by Yale School of Medicine researchers. The team also found that increasing the levels of this hormone, called FGF21, protects against the loss of immune function that comes with age.

12 Jan 2016

Bio2 Technologies receives 510(k) clearance from FDA for Fusion Implant system

Bio2 Technologies, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Fusion Implant system for interphalangeal fusion, fracture repair and osteotomies of the toes, fingers and other small bones in the presence of appropriate immobilization.

11 Jan 2016

DNA-binding protein acts like genetic traffic signal to orchestrate early stage embryonic development

New research by UC San Francisco stem cell biologists has revealed that a DNA-binding protein called Foxd3 acts like a genetic traffic signal, holding that ball of undifferentiated cells in a state of readiness for its great transformation in the third week of development.

11 Jan 2016

Braces halt further progression of spinal curve, surgery in adolescent scoliosis patients

Bracing often is recommended for adolescents diagnosed with idiopathic adolescent scoliosis, and a spinal curve between 25 and 45 degrees. When worn consistently and as directed, braces have been found to effectively halt or slow further progression of a spinal curve, often preventing surgery.

11 Jan 2016

MiMedx Group agrees to buy Stability Biologics

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has signed a definitive agreement to acquire Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities and distributors serving the surgical, spine and orthopedics sectors of the healthcare industry.

11 Jan 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

Integra Omnigraft Dermal Regeneration Matrix approved to treat certain diabetic foot ulcers

The U.S. Food and Drug Administration today approved a new indication for the Integra Omnigraft Dermal Regeneration Matrix (Omnigraft) to treat certain diabetic foot ulcers. The matrix device, which is made of silicone, cow collagen, and shark cartilage, is placed over the ulcer and provides an environment for new skin and tissue to regenerate and heal the wound.

7 Jan 2016

Drexel biomedical engineer identifies immune cell as potential strategy for growing blood vessels

In what could be a pivotal step toward repairing non-healing wounds and damaged organs, a Drexel University biomedical engineer has identified an immune cell as a potential strategy for growing blood vessels.

7 Jan 2016

Combining NELL-1 with BMP2 therapy may promote bone development

Bone morphogenetic protein-2 (BMP2) is used clinically to promote bone repair. However, the high BMP2 concentrations required to stimulate bone growth in humans may produce life-threatening adverse effects such as cervical swelling in spinal fusion procedures, a problem that prompted an FDA warning in 2008.

7 Jan 2016

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

With a median survival rate of just five to seven years, Mantle Cell Lymphoma (MCL) is considered the most aggressive known blood cancer -- and available therapies are scarce. Three thousand Americans are diagnosed with MCL every year, and despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research.

6 Jan 2016

Bone News and Research

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

Novel technique helps identify diabetic patients at risk of bone fractures

IMP, WEHI scientists successfully characterize central regulator of plasma cell function

New clinical imaging method may enable doctors to tackle lung infections

UConn-led researchers identify specific gene linked to Hajdu-Cheney syndrome

New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

IQWiG finds no added benefit for pomalidomide drug in multiple myeloma

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

Mechanical properties of bone revealed through micro-indentation testing

Increasing levels of FGF21 hormone protects against loss of immune function in the elderly

Bio2 Technologies receives 510(k) clearance from FDA for Fusion Implant system

DNA-binding protein acts like genetic traffic signal to orchestrate early stage embryonic development

Braces halt further progression of spinal curve, surgery in adolescent scoliosis patients

MiMedx Group agrees to buy Stability Biologics

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

Integra Omnigraft Dermal Regeneration Matrix approved to treat certain diabetic foot ulcers

Drexel biomedical engineer identifies immune cell as potential strategy for growing blood vessels

Combining NELL-1 with BMP2 therapy may promote bone development

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News